Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis
Status:
Recruiting
Trial end date:
2022-12-22
Target enrollment:
Participant gender:
Summary
- Evaluation of the microbiota modulation away from inflammation associated microbiota
profile Bacteroides2 (Bact2)
- Evaluation of the microbiota modulation potential of statins in Bact2- enterotyped,
healthy volunteers and ulcerative colitis patients.
- Evaluation of the effect of microbiota modulation on disease activity in ulcerative
colitis patients.
- Evaluation of reduced inflammatory parameters of participants involved in trial